These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10230747)

  • 21. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
    Luque CA; Rey JA
    Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
    McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
    Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A; Krause J
    JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
    JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
    Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study.
    Milano W; Petrella C; Casella A; Capasso A; Carrino S; Milano L
    Adv Ther; 2005; 22(1):25-31. PubMed ID: 15943219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
    Toubro S; Hansen DL; Hilsted JC; Porsborg PA; Astrup AV;
    Ugeskr Laeger; 2001 May; 163(21):2935-40. PubMed ID: 11402974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Obes Res; 1998 Jul; 6(4):285-91. PubMed ID: 9688105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sibutramine and the management of obesity.
    Poston WS; Foreyt JP
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK; Pekkarinen TA; Rissanen AM
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.